News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Emisphere Technologies, Inc. (EMIS) Reports Notification of First Interpretable Results on Phase III Study of Oral Calcitonin in Osteoporosis Patients


11/14/2011 9:54:53 AM

CEDAR KNOLLS, N.J., Nov. 14, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) ("Emisphere" or the "Company") announced today that it has been informed by Novartis Pharma AG ("Novartis") that Novartis has released first interpretable results (FIR) from its three-year Phase III Study 2303 assessing the safety and efficacy of oral calcitonin (SMC021) in the treatment of post-menopausal osteoporosis, conducted by its license partner Nordic Bioscience A/S ("Nordic Bioscience").

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES